Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H22N2O |
Molecular Weight | 246.348 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2
InChI
InChIKey=GJJFMKBJSRMPLA-HIFRSBDPSA-N
InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1
Molecular Formula | C15H22N2O |
Molecular Weight | 246.348 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23499664Curator's Comment: Description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022256s013lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499664
Curator's Comment: Description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022256s013lbl.pdf
Milnacipran is the only marketed serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI) reported to have greater relative potency at NET than SERT in vitro and is the first SNRI to report equal occupancy of both transporters at clinical doses. Milnacipran is a racemic mixture of the 1S, 2R (F2695/levomilnacipran) and 1R, 2S (F2696/dextromilnacipran) enantiomers. Savella® (Milnacipran) is indicated for the management of fibromyalgia.
Originator
Sources: http://adisinsight.springer.com/drugs/800000712 | https://www.google.com/patents/USRE43879
Curator's Comment: Milnacipran was synthesised as a racemic mixture at the PIERRE FABRE MEDICAMENT Research Centre (Castres, France).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499664 |
290.0 nM [Ki] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499664 |
16.9 nM [Ki] | ||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499664 |
139.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SAVELLA Approved UseSavella is indicated for the management of fibromyalgia. Savella is not approved for use in pediatric patients [see Use in Specific Populations (8.4) Launch Date1.2318912E12 |
|||
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
132 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26663198/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
150 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8923123/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1316.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26663198/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26663198/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8923123/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
87% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8923123/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
87% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
MILNACIPRAN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.593 |
unhealthy, 48.6 n = 181 Health Status: unhealthy Condition: Fibromyalgia Age Group: 48.6 Sex: M+F Population Size: 181 Sources: Page: p.593 |
Disc. AE: Nausea, Blood pressure increased... AEs leading to discontinuation/dose reduction: Nausea (2.4%) Sources: Page: p.593Blood pressure increased (1.4%) Heart rate increased (1%) |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Disc. AE: Suicidal ideation, Serotonin syndrome... AEs leading to discontinuation/dose reduction: Suicidal ideation Sources: Page: p.1Serotonin syndrome Neuroleptic malignant syndrome Blood pressure increased Heart rate increased Seizures Hepatotoxicity ALT increased (mild) Aspartate aminotransferase increase (mild) Hepatitis fulminant (rare) Bleeding |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Disc. AE: Nausea, Palpitations... AEs leading to discontinuation/dose reduction: Nausea (6%) Sources: Page: p.11Palpitations (3%) Headache (2%) Constipation (1%) Heart rate increased (1%) Hyperhidrosis (1%) Vomiting (1%) Dizziness (1%) |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.5 |
Disc. AE: Suicidal ideation... AEs leading to discontinuation/dose reduction: Suicidal ideation (1.3%) Sources: Page: p.5 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Heart rate increased | 1% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.593 |
unhealthy, 48.6 n = 181 Health Status: unhealthy Condition: Fibromyalgia Age Group: 48.6 Sex: M+F Population Size: 181 Sources: Page: p.593 |
Blood pressure increased | 1.4% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.593 |
unhealthy, 48.6 n = 181 Health Status: unhealthy Condition: Fibromyalgia Age Group: 48.6 Sex: M+F Population Size: 181 Sources: Page: p.593 |
Nausea | 2.4% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.593 |
unhealthy, 48.6 n = 181 Health Status: unhealthy Condition: Fibromyalgia Age Group: 48.6 Sex: M+F Population Size: 181 Sources: Page: p.593 |
Bleeding | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Blood pressure increased | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Heart rate increased | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Hepatotoxicity | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Neuroleptic malignant syndrome | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Seizures | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Serotonin syndrome | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Suicidal ideation | Disc. AE | 100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
ALT increased | mild Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Aspartate aminotransferase increase | mild Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Hepatitis fulminant | rare Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.1 |
Constipation | 1% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Dizziness | 1% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Heart rate increased | 1% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Hyperhidrosis | 1% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Vomiting | 1% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Headache | 2% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Palpitations | 3% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Nausea | 6% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.11 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.11 |
Suicidal ideation | 1.3% Disc. AE |
100 mg 2 times / day multiple, oral Recommended Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: Page: p.5 |
unhealthy Health Status: unhealthy Condition: Fibromyalgia Sources: Page: p.5 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=27 Page: 27.0 |
no | |||
Page: 18.0 |
no | |||
Page: 18.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=27 Page: 27.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=27 Page: 27.0 |
no | |||
Page: 18.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=27 Page: 27.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=27 Page: 27.0 |
no | |||
Page: 18.0 |
no | |||
Page: 18.0 |
no | |||
Page: 18.0 |
no | |||
Page: 18.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=27 Page: 27.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=7 Page: 7.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
no | no (co-administration study) Comment: no changes in PK of warfarin or milnacipran were observed Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
no | unlikely (co-administration study) Comment: when coadministered with carbamazepine, exposure (Cmax and AUC) to milnacipran decreased by 18% and 19%, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
no | unlikely (co-administration study) Comment: At steady state, Cmax and AUC for milnacipran increased by only 10% and 20% when coadministered with levomepromazine; no changes in PK of warfarin or milnacipran were observed Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
no | unlikely (co-administration study) Comment: when coadministered with carbamazepine, exposure (Cmax and AUC) to milnacipran decreased by 18% and 19%, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_ClinPharmR_P1.pdf#page=55 Page: 55.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022256s000_PharmR_P2.pdf#page=59 Page: 59.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Which bioequivalence study for a racemic drug? Application to milnacipran. | 1998 Apr-Jun |
|
High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. | 2001 Sep 25 |
|
Remarkable effect of milnacipran in the treatment of Japanese major depressive patients. | 2002 Jun |
|
Clinical utility of milnacipran in comparison with other antidepressants. | 2002 Jun |
|
Pharmacology and pharmacokinetics of milnacipran. | 2002 Jun |
|
Silent thyroiditis associated with short-term lithium therapy. | 2002 Nov-Dec |
|
[Experience with ixel (milnacipran hydrochloride) use in the treatment of patients with post-stroke depression]. | 2003 |
|
[Pharmacokinetics and drug interaction of antidepressants and anti-manic drugs]. | 2003 |
|
Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. | 2003 Dec |
|
Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. | 2003 Dec |
|
Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran. | 2003 Jan |
|
Favorable effect of milnacipran on depression induced by interferon-alpha. | 2003 Spring |
|
Milnacipran treatment of a terminally ill cancer patient with major depressive disorder. | 2004 Aug |
|
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. | 2004 Aug |
|
Prevalence of induced mania in patients treated with milnacipran: a comparison with paroxetine. | 2004 Aug |
|
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. | 2004 Feb 1 |
|
Reboxetine: a norepinephrine selective reuptake pump inhibitor. | 2004 Jan |
|
A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. | 2004 Jul |
|
Subjective and polysomnographic effects of milnacipran on sleep in depressed patients. | 2004 Jul |
|
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. | 2004 Nov |
|
Serotonin and noradrenaline reuptake inhibitors in animal models of pain. | 2004 Oct |
|
A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. | 2004 Oct |
|
Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. | 2004 Sep |
|
Effectiveness of milnacipran for the treatment of chronic pain: a case series. | 2004 Sep-Oct |
|
[Effects of milnacipran on neuronal excitability and synaptic transmission in neurons of the rat locus coeruleus]. | 2005 Jan |
|
Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action. | 2005 Jul |
Sample Use Guides
Milnacipran and the L enantiomer were effective in reducing immobility in the forced swim test in rodents (EC50 ~10 mg/kg PO and ~3 mg/kg PO, respectively) compared with D enantiomer (EC50 ≥100 mg/kg PO).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23499664
Dextromilnacipran inhibits norepinephrine and serotonin reuptake in rat hypothalamic synaptosomes with IC50 values of 750 and 600 nM, respectively
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:02:21 UTC 2023
by
admin
on
Thu Jul 06 00:02:21 UTC 2023
|
Record UNII |
G56VK1HF36
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29747
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
WHO-VATC |
QN06AX17
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
IMPULSOR (REFUSED, FIBROMYALGIA)
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
NDF-RT |
N0000000109
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
NDF-RT |
N0000175749
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
NDF-RT |
N0000000102
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
LIVERTOX |
NBK547960
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
MILNACIPRAN PIERRE FABRE MEDICAMENT (REFUSED: FIBROMYALGIA)
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
WHO-ATC |
N06AX17
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
IMPULSOR (REFUSED: FIBROMYALGIA)
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C048107
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
588250
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | RxNorm | ||
|
MILNACIPRAN
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
C78021
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
7436
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
CHEMBL259209
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
G56VK1HF36
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
100000080634
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
DTXSID3048287
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
M7545
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | Merck Index | ||
|
Milnacipran
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
DB04896
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
5701
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
G56VK1HF36
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
1808
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
92623-85-3
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY | |||
|
SUB08965MIG
Created by
admin on Thu Jul 06 00:02:21 UTC 2023 , Edited by admin on Thu Jul 06 00:02:21 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
BINDER->LIGAND |
The plasma protein binding of milnacipran is approximately 13% and is independent of the concentration (Study# M013).
BINDING
|
||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
Lower than detection limit in plasma
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Absolute Bioavailability | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||